PF-1355 is primarily utilized in the field of medical research, particularly in the study of metabolic disorders. It functions as a potent and selective inhibitor of 12/15-lipoxygenase, an enzyme involved in the inflammatory and oxidative stress pathways. By inhibiting this enzyme, PF-1355 helps researchers explore potential therapeutic interventions for conditions such as diabetes, atherosclerosis, and neurodegenerative diseases. Its application extends to preclinical studies where it is used to understand the role of lipid peroxidation and inflammation in disease progression. Additionally, PF-1355 is employed in experimental models to evaluate its efficacy in reducing tissue damage and improving metabolic outcomes, providing valuable insights for the development of new treatments targeting metabolic and inflammatory pathways.